Homepage

Account:
GRBI Demo

Topic:
Pancreatic & breast cancer

Outsourced Competitive & Strategic Intelligence for the Life Science Industry

We support our Life Sciences partners in developing and marketing innovative patient treatments globally. Whether you are a small biotech or a large pharmaceutical company we have the right solution for you.

Recent Insights
Poster: A phase 1b study of Nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)
May 29, 2020 ASCO Poster Insights

Read More
Poster: An analysis of Nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (Checkmate 238)
May 29, 2020 ASCO Poster Insights

Read More
Poster: A phase 2, randomized study of Nivolumab (NIVO), NIVO plus Linrodostat Mesylate, or NIVO plus Intravesical Bacillus Calmette-Guerin (BCG)
May 29, 2020 ASCO Poster Insights

Read More
Executive Summary
Oct 18, 2019 ESMO Summary

Read More
Poster Discussion – GI Tumors, Non-Colorectal: Nab-pac/gem is more effective than
Oct 18, 2019 ESMO Poster Insights

Read More
Poster Discussion – GI Tumors, Non-Colorectal: POLO – Health-related QoL of
Oct 18, 2019 ESMO Poster Insights

Read More
Special Symposium:
Oct 18, 2019 ESMO Session Insights

Read More
Special Symposium – ESMO Colloquium (Celgene): Pancreatic Cancer –
Oct 18, 2019 ESMO Session Insights

Read More
APACT Subgroup Analysis
Oct 18, 2019 ESMO Poster Insights

Read More
KOL and Respondent Insights | 1 of 3
Oct 18, 2019 ESMO Session Insights

Read More
Executive Summary
Jun 19, 2019 ASCO Summary

Read More
Boston Biomedical
Jun 19, 2019 ASCO Results

Read More
Meet the Professor Session: Gastric and Pancreatic Cancer Screening in
Jun 19, 2019 ASCO Session Insights

Read More
Peer View Educational Session: The Pancreatic Cancer Case Book: Taking
Jun 19, 2019 ASCO Session Insights

Read More
Educational Session: Reprogramming the Tumor Microenvironment to
Jun 19, 2019 ASCO Session Insights

Read More
Plenary Session incl. the Distinguished Achievement Award and Science of
Jun 19, 2019 ASCO Session Insights

Read More
Meet the Professors: Chemotherapy, Radiation, Surgery, and
Jun 19, 2019 ASCO Session Insights

Read More
Poster Discussion: Gastrointestinal Cancer (non-colorectal) | 1 of 2
Jun 19, 2019 ASCO Session Insights

Read More
MEDIPLEX: A P1 Study of Durvalumab Combined with Pexidartinib in
Jun 19, 2019 ASCO Poster Insights

Read More
Methylated Circulating Tumor DNA as a Independent Prognostic Factor in
Jun 19, 2019 ASCO Poster Insights

Read More
Randomized P2 study of 2L modified FOLFIRI with PARP inhibitor veliparib
Jun 19, 2019 ASCO Poster Insights

Read More
Final Report of a P1/2 study of veliparib in combination with 5-FU and
Jun 19, 2019 ASCO Poster Insights

Read More
Improved OS for PDAC Patients Enrolled in the Know Your Tumor (KYT)
Jun 19, 2019 ASCO Poster Insights

Read More
TEDOPaM – PRODIGE 63 GERCOR D17-01 Study. P2 Study of Maintenance
Jun 19, 2019 ASCO Poster Insights

Read More
Randomized P2 Study of Niraparib + Nivolumab or Ipilimumab in patients
Jun 19, 2019 ASCO Poster Insights

Read More
Neoadjuvant FOLFIRINOX vs Adjuvant Gemcitabine in PDAC (A Wolfe et al)
Jun 19, 2019 ASCO Poster Insights

Read More
KOL and Respondent Insights | 1 of 3
Jun 19, 2019 ASCO Session Insights

Read More
KOL and Respondent Insights | 2 of 3
Jun 19, 2019 ASCO Session Insights

Read More
Executive Summary | 1 of 2
Jun 17, 2019 ASCO Session Insights

Read More
Executive Summary | 2 of 2
Jun 17, 2019 ASCO Session Insights

Read More
Breast Cancer – Metastatic
Jun 17, 2019 ASCO Results

Read More
Molecular Profiling in Breast Cancer: Past, Present, and Future
Jun 17, 2019 ASCO Results

Read More
Novel Therapeutics in Breast Cancer: Crossing the Subtype Divide
Jun 17, 2019 ASCO Session Insights

Read More
“I think these data, from the MONALESSA-7 trial are going to
Jun 17, 2019 ASCO Session Insights

Read More
TRINITI-1 Trial – Triplet therapy (Ribociclib, Everolimus and Exemestane)
Jun 17, 2019 ASCO Session Insights

Read More
Oral Paclitaxel in the Treatment of mBC Patients
Jun 17, 2019 ASCO Session Insights

Read More
Next-Gen Sequencing (NGS) Results Among HR+/HER2- mBC Patients Treated with a CDK4/6 Inhibitor
Jun 17, 2019 ASCO Results

Read More
Immunotherapy Predictive Biomarkers in Metastatic Breast Cancer
Jun 17, 2019 ASCO Session Insights

Read More
Everolimus and Exemestane
Jun 17, 2019 ASCO Session Insights

Read More
VERONICA: Venetoclax + Fulvestrant vs. Fulvestrant
Jun 17, 2019 ASCO Session Insights

Read More
Balixafortide (a CXCR4 antagonist) + Eribulin
Jun 17, 2019 ASCO Session Insights

Read More
COMET Study: Multimodality Liquid Biopsy for Early Monitoring and
Jun 17, 2019 ASCO Session Insights

Read More
Further requirements
Feb 10, 2021 Landscape Summary

Read More
Executive Summary – Phase III
Oct 18, 2019 Landscape Summary

Read More
Summary: Phase III Trial Timeline – 2nd Line
Oct 18, 2019 Landscape Trials Review

Read More
Phase III Trial Update – First Line Therapy
Oct 18, 2019 Landscape Trials Review

Read More
Phase III Trial Update – First Line Therapy
Oct 18, 2019 Landscape Trials Review

Read More
Executive Summary – ASCO and ESMO GI 2019
Jul 18, 2019 Landscape Summary

Read More
Executive Summary – Clinical Trials
Jul 18, 2019 Landscape Summary

Read More
Summary: Phase III Trial Timeline
Jul 18, 2019 Landscape Trials Review

Read More
Phase III Trial Update
Jul 18, 2019 Landscape Trials Review

Read More
Phase III Trial Update
Jul 18, 2019 Landscape Trials Review

Read More
Phase II/III Trial Update
Jul 18, 2019 Landscape Trials Review

Read More
Preclinical Trial Details Update
Jul 18, 2019 Landscape Trials Review

Read More
Phase II Trial Update
Jul 18, 2019 Landscape Trials Review

Read More
Phase I/II Trial Details
Jul 18, 2019 Landscape Trials Review

Read More
Phase I/II Trial Details
Jul 18, 2019 Landscape Trials Review

Read More
Phase I/II Trial Details
Jul 18, 2019 Landscape Trials Review

Read More
Phase I/II Trial Details
Jul 18, 2019 Landscape Trials Review

Read More
Phase I Trial Details
Jul 18, 2019 Landscape Trials Review

Read More
Phase I Trial Details
Jul 18, 2019 Landscape Trials Review

Read More
Preclinical Trial Details
Jul 18, 2019 Landscape Trials Review

Read More
Preclinical Trial Details
Jul 18, 2019 Landscape Trials Review

Read More
Preclinical Trial Details
Jul 18, 2019 Landscape Trials Review

Read More
Preclinical Trial Details
Jul 18, 2019 Landscape Trials Review

Read More
Preclinical Trial Details
Jul 18, 2019 Landscape Trials Review

Read More